Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 daahirnimo>98.0% (GC) Lenvatinib Mesylate Warshada Dhexe

Sharaxaad Gaaban:

Magaca Kiimikada: Methyl 4-Amino-2-Methoxybenzoate

CAS: 27492-84-8

Daahirsanaanta:>98.0% (GC)

Muuqashada: Caddaan ilaa Banaan-cad budada ama kiristaalo

Dhexdhexaadiyaha Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Faahfaahinta Alaabta

Alaabooyinka La Xiriira

Tags Product

Sharaxaad:

Guryaha Kiimikada:

Magaca Kiimikada Methyl 4-Amino-2-Methoxybenzoate
La mid ah 4-Amino-2-Methoxybenzoic Acid Methyl Ester;Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester
Lambarka CAS 27492-84-8
Lambarka CAT RF-PI1974
Heerka Saamiyada Kaydka dhexdiisa, Qiyaasta Waxsoosaarka Ilaa Tan
Qaanuunka molecular C9H11NO3
Miisaanka Molecular 181.19
Cufnaanta 1.179±0.060 g/cm3
Summada Kiimikada Ruifu

Tilmaamaha:

Shayga Tilmaamaha
Muuqashada Caddaan ama budo ama kiristaalo
Daahirnimada / Habka Falanqaynta >98.0% (GC)
Daahirnimada / Habka Falanqaynta 97.5 ~ 102.5 (Titration Nonaqueous)
Meesha dhalaalaysa 157.0 ~ 161.0 ℃
Khasaare xagga qalajinta <1.00%
Wadarta wasakhda <2.0%
Infrared Spectrum Waafaqsan Qaab-dhismeedka
Proton NMR Spectrum Waafaqsan Qaab-dhismeedka
Heerka Imtixaanka Heerka Ganacsiga
Isticmaalka Dhexdhexaadiyaha Lenvatinib Mesylate (CAS: 857890-39-2)

Xidhmada & Kaydinta:

Xidhmada: Dhalo, bacda bireed aluminium, 25kg / Durbaan kartoonada, ama sida waafaqsan shuruudaha macmiilka

Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka

Faa'iidooyinka

1

FAQ:

Codsiga:

Methyl 4-Amino-2-Methoxybenzoate (CAS: 27492-84-8) waxaa loo isticmaali karaa dhex dhexaadnimada Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib waa dawada kansarka qanjirka tayroodhka oo ay soo saartay Eisai Corporation of Japan (Code: E7080), oo iska leh xannibaadaha tyrosine kinase ee afka laga qaato (RTK) waxayna joojin kartaa dhaqdhaqaaqa kinase ee xuubka kobaca endothelial vascular VEGFR1 (VEGF). FLT1), VEGFR2 (KDR), iyo VEGFR3 (FLT4).Lenvatinib waxa kale oo uu joojin karaa ku lug lahaanshaha RTK-yada kale ee angiogenesis-ka pathological, koritaanka burooyinka, iyo horumarka kansarka marka laga reebo hawlahooda gacanta ee caadiga ah oo ay ku jiraan fayraska koritaanka fibroblast (FGF) receptors FGFR1, 2, 3, iyo 4;Soo-dhoweeyaha korriinka ee platelet-derived (PDGFR [alpha]), KIT, iyo RET.[Tilmaanta]: Lenvatinib waxay ku habboon tahay daaweynta bukaannada kansarka tayroodh ee soo noqnoqda deegaanka ama nooca metastasis, nooca horumarka iyo shucaaca iodine-refractory nooc kala duwan.Febraayo 13, 2015, US FDA waxay ansixisay dawada ka hortagga kansarka ee Lenvatinib si loogu daweeyo kansarka tayroodhka.Lenvatinib waa inhibitor-bartilmaameedka enzyme-ka badan, isagoo awood u leh inuu xakameeyo VEGFR2 iyo VEGFR3 (receptor endothelial factor factor receptor).Magaca ganacsiga ee Lenvatinib waa Lenvima.Maajo 20, 2015, Hay'adda Daawooyinka Yurub (EMA) ayaa u ogolaatay Lenvatinib daawaynta caabuqa, gudaha hore u maray ama kala-duwanaanta metastatic (papillary, follicular, nooca Hurthle) kansarka tayroodhka (DTC).Tijaabada dhexdeeda, wakhtiga badbaadada dhexdhexaadka ah ee bukaanada DTC shucaaca iodine-refractory ee lagu daweeyay Lenvatinib waxay ahayd 18 bilood halka qiimaha bukaanada qaata placebo ay tahay 3 bilood oo keliya.

Halkan ku qor fariintaada oo noo soo dir